-
Call to add Nazi camps to UNESCO list
-
England cricket chiefs to front up to media over Ashes flop
-
'Miracle': Europe reconnects with lost spacecraft
-
Nigeria 'challenged by terrorism', president says on UK state visit
-
Woltemade deployed too deep to be dangerous at Newcastle, says Nagelsmann
-
Wimbledon expansion plan gets legal boost
-
EU summit fails to rally Orban behind stalled Ukraine loan
-
New Morocco coach praises 'well-deserved' Cup of Nations decision
-
Senegal to appeal CAF Africa Cup of Nations decision
-
'Mixing things up': Nagelsmann goes for flexibility in new Germany squad
-
Record-setter Hodgkinson hopes 'fourth time lucky' at world indoors
-
Atletico target Romero says his focus on Spurs' survival bid
-
Karalis hits prime form to threaten Duplantis surprise
-
Freshly returned Mbappe leads France squad for Brazil, Colombia friendlies
-
US earns its lowest-ever score on freedom index
-
Europe's super elite teach English clubs a Champions League lesson
-
What we know about the UK's deadly meningitis outbreak
-
Karl handed Germany debut as Musiala misses out with injury
-
What cargo ships are passing Hormuz strait?
-
Bank of England holds interest rate amid Middle East war
-
Energy prices soar, Iran and US trade threats after Qatar gas hit
-
'Surreal' for F1 world champion Norris to have Tussauds waxwork
-
Iran hangs three men in first executions over January protests
-
North Korea, Philippines qualify for 2027 Women's World Cup
-
Man Utd boss Carrick expects hard test against resolute Bournemouth
-
Oil prices surge, stocks sink on energy shock fears
-
Alibaba pins hopes on AI as quarterly net profit drops
-
Oil soars 10% after Qatar energy sites hit in Mideast war
-
Defiant Orban digs in over blocked Ukraine loan at EU talks
-
Iran 'boycotting' USA but not World Cup: football federation chief
-
Tokyo's dazzling cherry blossom season officially begins
-
Energy prices surge, stocks sink amid rising energy shock fears
-
Iran causes 'extensive' damage to Qatar gas hub, sparks Trump warning
-
Baby monkey Punch acclimatising, making new friends at Japan zoo
-
Labubu creators hope for monster film hit in Sony co-production
-
Kings of K-pop: What to know about BTS's comeback
-
Patching the wounds of Kinshasa's street children
-
Thailand's Anutin: Millionaire PM with a populist approach
-
In Seoul square of protest and history, BTS fans welcome grand comeback
-
Hong Kong panel hears safety measures failed on day of deadly fire
-
Trump threatens to destroy Iran's largest gas field
-
Doncic and James power Lakers over Rockets as win streak hits seven
-
Inter continue Serie A title hunt ahead of Italy's date with World Cup destiny
-
Strait of Hormuz blockage drives up Gulf food bills
-
Ahead of election, Danish city mirrors country's challenges
-
Wild possum shelters with plush toys in Australian airport shop
-
Iran missile fire kills 3 Palestinians in West Bank, foreign worker in Israel
-
Asian Games cruise ship and wooden huts will be 'unique experience'
-
Pacific nations fear fuel shortages as Middle East war sends oil prices soaring
-
World indoor athletics championships: five stand-out events
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
N.Fournier--BTB